Redeye: Deep value galore in InDex Pharmaceuticals

Redeye hereby initiates coverage of InDex Pharmaceuticals, with a fair value in our Base Case offering over 130% upside from the current price. Responsible analyst is Mathias Spinnars from the Life Science team. Read more and download the full report: https://goo.gl/S0kTcj

Become a member at Redeye in order to follow the company and get access to the latest analyses and updates.

This is a press release from Redeye - Research Powered Investment Banking. http://beta.redeye.se/

Taggar: